ReviewInternational journal of molecular sciences2022
Mechanisms of Systemic Osteoporosis in Rheumatoid Arthritis.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- Association between osteoporosis and arthritis: Results from the NHANES and Mendelian randomization study.Metabolism open · 2026Article
- Bone Health in Rheumatoid Arthritis: An Update.Current rheumatology reports · 2026Review
- Periodontitis as a Model for Inflammatory Uncoupling of Bone Remodeling.Journal of periodontal research · 2026Review
- Article
- Inflammation-related composite indices and their association with osteoporosis and fragility fractures in rheumatoid arthritis.Arthritis research & therapy · 2026Article
- Geroscience insights into difficult-to-treat rheumatoid arthritis: the role of unhealthy aging, comorbidity, and therapeutic complexity.GeroScience · 2026Review
- Skeletal effects of JAK1/2 inhibition versuFrontiers in pharmacology · 2026Article
- Healthcare Interventions in the Management of Rheumatic Diseases: A Narrative Analysis of Effectiveness and Emerging Strategies.Healthcare (Basel, Switzerland) · 2025Review
- Where Do We Stand in the Management of Rheumatoid Arthritis Ahead of EULAR/ACR 2025?Clinics and practice · 2025Review
- Systemic Inflammation and Disruption of the Local Microenvironment Compromise Muscle Regeneration: Critical Pathogenesis of Autoimmune-Associated Sarcopenia.Interactive journal of medical research · 2025Article
- Disease activity score is associated with vertebral fragility fractures in patients with rheumatoid arthritis: a cross-sectional multidisciplinary study.Rheumatology international · 2025Article
- The Inflammatory Link of Rheumatoid Arthritis and Thrombosis: Pathogenic Molecular Circuits and Treatment Approaches.Current issues in molecular biology · 2025Review
- Article
- International overview on juvenile-, adult- and elderly-onset rheumatoid arthritis: The age at disease onset as a fundamental determinant of clinical presentation.Clinical rheumatology · 2025Article
- Article
- Weight-adjusted waist index associated with bone mineral density in rheumatoid arthritis patients: a cross-sectional study.Clinical rheumatology · 2025Article
- Osteoimmunology of Osteoporosis in Rheumatoid Arthritis: Emerging Mechanisms and Therapeutic Implications.International journal of general medicine · 2025Review
- Extending the Therapeutic Potential: Romosozumab in Osteoporosis Management.Journal of the Endocrine Society · 2024Review
- Curcumin-loaded scaffolds in bone regeneration.Heliyon · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA), an autoimmune disease, is characterized by the presence of symmetric polyarthritis predominantly of the small joints that leads to severe cartilage and bone destruction. Based on animal and human data, the pathophysiology of osteoporosis, a frequent comorbidity in conjunction with RA, was delineated. Autoimmune inflammatory processes, which lead to a systemic upregulation of inflammatory and osteoclastogenic cytokines, the production of autoantibodies, and Th cell senescence with a presumed disability to control the systemic immune system's and osteoclastogenic status, may play important roles in the pathophysiology of osteoporosis in RA. Consequently, osteoclast activity increases, osteoblast function decreases and bone metabolic and mechanical properties deteriorate. Although a number of disease-modifying drugs to treat joint inflammation are available, data on the ability of these drugs to prevent fragility fractures are limited. Thus, specific treatment of osteoporosis should be considered in patients with RA and an associated increased risk of fragility fractures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.